CO2024009492A2 - Composición y método para inhibir la expresión de proteína lpa(apo(a)) - Google Patents
Composición y método para inhibir la expresión de proteína lpa(apo(a))Info
- Publication number
- CO2024009492A2 CO2024009492A2 CONC2024/0009492A CO2024009492A CO2024009492A2 CO 2024009492 A2 CO2024009492 A2 CO 2024009492A2 CO 2024009492 A CO2024009492 A CO 2024009492A CO 2024009492 A2 CO2024009492 A2 CO 2024009492A2
- Authority
- CO
- Colombia
- Prior art keywords
- lpa
- composition
- expression
- apo
- inhibiting
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/312—Phosphonates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/314—Phosphoramidates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2022073415 | 2022-01-24 | ||
| PCT/CN2023/073456 WO2023138689A1 (zh) | 2022-01-24 | 2023-01-23 | 抑制LPA(Apo(a))蛋白表达的组合物和方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2024009492A2 true CO2024009492A2 (es) | 2024-10-31 |
Family
ID=87347910
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2024/0009492A CO2024009492A2 (es) | 2022-01-24 | 2024-07-18 | Composición y método para inhibir la expresión de proteína lpa(apo(a)) |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US20250297250A1 (enExample) |
| EP (1) | EP4471144A4 (enExample) |
| JP (2) | JP7833044B2 (enExample) |
| KR (1) | KR20240135657A (enExample) |
| CN (1) | CN118679259A (enExample) |
| AU (1) | AU2023210010A1 (enExample) |
| CA (1) | CA3248387A1 (enExample) |
| CL (1) | CL2024002168A1 (enExample) |
| CO (1) | CO2024009492A2 (enExample) |
| DO (1) | DOP2024000141A (enExample) |
| IL (1) | IL314060A (enExample) |
| JO (1) | JOP20240159A1 (enExample) |
| MX (1) | MX2024008989A (enExample) |
| PE (1) | PE20250779A1 (enExample) |
| TW (1) | TW202345865A (enExample) |
| WO (1) | WO2023138689A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020150473A2 (en) | 2019-01-18 | 2020-07-23 | Dogma Therapeutics, Inc. | Pcsk9 inhibitors and methods of use thereof |
| BR112021013924A2 (pt) | 2019-01-18 | 2021-09-21 | Astrazeneca Ab | Inibidores de pcsk9 e métodos de uso do mesmo |
| KR20240103025A9 (ko) | 2021-11-16 | 2025-12-10 | 상하이 아르고 바이오파마슈티칼 씨오., 엘티디. | 안지오텐시노겐(agt) 단백질의 발현을 저해하는 조성물 및 방법 |
| AU2023404700A1 (en) * | 2022-12-02 | 2025-07-10 | Shanghai Argo Biopharmaceutical Co., Ltd. | Bicyclic abasic nucleic acid analogs and oligomeric compounds prepared therefrom |
| CN119506275A (zh) * | 2023-08-22 | 2025-02-25 | 苏州炫景生物科技有限公司 | 抑制lpa基因表达的双链寡核苷酸及其应用 |
| UY40897A (es) * | 2023-09-21 | 2025-03-31 | Ionis Pharmaceuticals Inc | Compuestos y métodos para inhibir lpa |
| WO2025082059A1 (zh) * | 2023-10-16 | 2025-04-24 | 润佳(上海)医药技术有限公司 | 经修饰的dsRNA、双链RNAi剂及其用途 |
| CN120344664A (zh) * | 2023-10-27 | 2025-07-18 | 北京安龙生物医药有限公司 | 靶向脂蛋白a的寡核苷酸及其用途 |
| CN120020252A (zh) * | 2023-11-17 | 2025-05-20 | 纳肽得(青岛)生物医药有限公司 | 抑制LPA表达的siRNA及其用途 |
| CN122514601A (zh) * | 2023-11-29 | 2026-08-04 | 美国圣因生物股份有限公司 | 靶向Lp(a)的小干扰RNA及其用途 |
| TW202546233A (zh) * | 2024-02-05 | 2025-12-01 | 美商靖因藥業（上海）有限公司 | 用於抑制ｌｐ（ａ）或ａｐｏｃ３之表現的多核酸分子、醫藥組合物及其用途 |
| WO2025252159A1 (zh) * | 2024-06-06 | 2025-12-11 | 大睿生物医药科技(上海)有限公司 | 调控LPA表达的dsRNA分子 |
| WO2026026890A1 (zh) * | 2024-07-31 | 2026-02-05 | 前沿生物药业(南京)股份有限公司 | 用于抑制LPA基因表达的siRNA及其修饰物与应用 |
| WO2026092650A1 (zh) * | 2024-11-01 | 2026-05-07 | 迈威(上海)生物科技股份有限公司 | 一种抑制LPA基因表达的RNAi制剂及其应用 |
| WO2026131490A1 (en) * | 2024-12-20 | 2026-06-25 | Ribocure Pharmaceuticals Ab | Oligonucleotide, oligonucleotide conjugate and composition, and use thereof |
| WO2026133253A1 (en) | 2024-12-20 | 2026-06-25 | Novartis Ag | Combinations of antisense agents, pharmaceutical compositions and methods of use |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3854480A (en) | 1969-04-01 | 1974-12-17 | Alza Corp | Drug-delivery system |
| US4675189A (en) | 1980-11-18 | 1987-06-23 | Syntex (U.S.A.) Inc. | Microencapsulation of water soluble active polypeptides |
| US4452775A (en) | 1982-12-03 | 1984-06-05 | Syntex (U.S.A.) Inc. | Cholesterol matrix delivery system for sustained release of macromolecules |
| US5075109A (en) | 1986-10-24 | 1991-12-24 | Southern Research Institute | Method of potentiating an immune response |
| US5211657A (en) | 1988-11-07 | 1993-05-18 | The United States Government As Represented By The Secretary Of The Department Of Health And Human Services | Laminin a chain deduced amino acid sequence, expression vectors and active synthetic peptides |
| US5133974A (en) | 1989-05-05 | 1992-07-28 | Kv Pharmaceutical Company | Extended release pharmaceutical formulations |
| US5032401A (en) | 1989-06-15 | 1991-07-16 | Alpha Beta Technology | Glucan drug delivery system and adjuvant |
| US5407686A (en) | 1991-11-27 | 1995-04-18 | Sidmak Laboratories, Inc. | Sustained release composition for oral administration of active ingredient |
| EP0804249A2 (en) | 1994-03-15 | 1997-11-05 | Brown University Research Foundation | Polymeric gene delivery system |
| US5736152A (en) | 1995-10-27 | 1998-04-07 | Atrix Laboratories, Inc. | Non-polymeric sustained release delivery system |
| US7740861B2 (en) | 2004-06-16 | 2010-06-22 | University Of Massachusetts | Drug delivery product and methods |
| CA2622583A1 (en) * | 2005-09-15 | 2007-03-22 | Henrik Frydenlund Hansen | Rna antagonist compounds for the inhibition of apo-b100 expression |
| CN101292034A (zh) * | 2005-09-15 | 2008-10-22 | 桑塔里斯制药公司 | 抑制apo-b100表达的rna拮抗化合物 |
| RU2624028C2 (ru) * | 2012-05-24 | 2017-06-30 | Ионис Фармасьютикалз, Инк. | Способы и композиции для модулирования экспрессии аполипопротеина (а) |
| PL2992098T3 (pl) * | 2013-05-01 | 2019-09-30 | Ionis Pharmaceuticals, Inc. | Kompozycje i sposoby modulowania ekspresji hbv i ttr |
| JOP20170056B1 (ar) * | 2016-09-02 | 2021-08-17 | Arrowhead Pharmaceuticals Inc | مركبات ترابطية مستهدفة |
| SG11201912178VA (en) * | 2017-09-11 | 2020-01-30 | Arrowhead Pharmaceuticals Inc | Rnai agents and compositions for inhibiting expression of apolipoprotein c-iii (apoc3) |
| EP3483270A1 (en) * | 2017-11-13 | 2019-05-15 | Silence Therapeutics GmbH | Products and compositions |
| CN119120476A (zh) * | 2017-11-13 | 2024-12-13 | 赛伦斯治疗有限责任公司 | 用于抑制细胞中lpa的表达的核酸 |
| AU2019380628B2 (en) * | 2018-11-13 | 2024-10-31 | Silence Therapeutics Gmbh | Nucleic acids for inhibiting expression of LPA in a cell |
| JP7507495B2 (ja) * | 2018-12-28 | 2024-06-28 | スーチョウ リボ ライフ サイエンス カンパニー、リミテッド | 核酸、当該核酸を含む組成物及び複合体ならびに調製方法と使用 |
| EP3923989A1 (en) | 2019-03-21 | 2021-12-22 | Mitotherapeutix LLC | Multivalent ligand clusters for targeted delivery of therapeutic agents |
| JP7827623B2 (ja) * | 2019-12-09 | 2026-03-10 | アムジエン・インコーポレーテツド | ＬＰＡ発現を阻害するためのＲＮＡｉコンストラクト及び方法 |
| EP4229201A1 (en) * | 2020-10-16 | 2023-08-23 | Sanofi | Rna compositions and methods for inhibiting lipoprotein(a) |
| US20250283076A1 (en) * | 2021-09-14 | 2025-09-11 | Argonaute RNA Limited | Treatment of cardiovascular disease |
| WO2023041079A1 (zh) * | 2021-09-18 | 2023-03-23 | 上海金中锘美生物医药科技有限公司 | Lpa抑制剂及其用途 |
| WO2024035898A2 (en) * | 2022-08-11 | 2024-02-15 | Sirius Therapeutics, Inc. | Polynucleic acid molecules for inhibiting expression of lp(a), pharmaceutical compositions, and uses thereof |
-
2023
- 2023-01-18 TW TW112102207A patent/TW202345865A/zh unknown
- 2023-01-23 KR KR1020247027597A patent/KR20240135657A/ko active Pending
- 2023-01-23 EP EP23743004.6A patent/EP4471144A4/en active Pending
- 2023-01-23 IL IL314060A patent/IL314060A/en unknown
- 2023-01-23 AU AU2023210010A patent/AU2023210010A1/en active Pending
- 2023-01-23 JP JP2024543113A patent/JP7833044B2/ja active Active
- 2023-01-23 MX MX2024008989A patent/MX2024008989A/es unknown
- 2023-01-23 CN CN202380021107.1A patent/CN118679259A/zh active Pending
- 2023-01-23 WO PCT/CN2023/073456 patent/WO2023138689A1/zh not_active Ceased
- 2023-01-23 CA CA3248387A patent/CA3248387A1/en active Pending
- 2023-01-23 US US18/730,467 patent/US20250297250A1/en active Pending
- 2023-01-23 PE PE2024001638A patent/PE20250779A1/es unknown
-
2024
- 2024-07-18 CL CL2024002168A patent/CL2024002168A1/es unknown
- 2024-07-18 CO CONC2024/0009492A patent/CO2024009492A2/es unknown
- 2024-07-19 DO DO2024000141A patent/DOP2024000141A/es unknown
- 2024-07-21 JO JOJO/P/2024/0159A patent/JOP20240159A1/ar unknown
-
2025
- 2025-05-01 US US19/196,722 patent/US20250257356A1/en active Pending
-
2026
- 2026-03-06 JP JP2026036105A patent/JP2026116903A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20240135657A (ko) | 2024-09-11 |
| TW202345865A (zh) | 2023-12-01 |
| DOP2024000141A (es) | 2024-10-15 |
| PE20250779A1 (es) | 2025-03-14 |
| EP4471144A4 (en) | 2026-01-21 |
| US20250257356A1 (en) | 2025-08-14 |
| IL314060A (en) | 2024-09-01 |
| JOP20240159A1 (ar) | 2024-07-21 |
| JP7833044B2 (ja) | 2026-03-18 |
| CL2024002168A1 (es) | 2025-01-10 |
| MX2024008989A (es) | 2024-07-29 |
| CN118679259A (zh) | 2024-09-20 |
| EP4471144A1 (en) | 2024-12-04 |
| CA3248387A1 (en) | 2025-07-09 |
| US20250297250A1 (en) | 2025-09-25 |
| WO2023138689A1 (zh) | 2023-07-27 |
| AU2023210010A1 (en) | 2024-07-25 |
| JP2026116903A (ja) | 2026-07-14 |
| JP2025504863A (ja) | 2025-02-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2024002168A1 (es) | Composición y método para inhibir la expresión de proteína lpa(apo(a)) | |
| ECSP24036299A (es) | Composiciones y métodos para inhibir la expresión de la proteína angiotensinógeno (agt) | |
| CL2021002326A1 (es) | Composiciones de arni contra el angiotensinógeno (agt) y métodos para su uso (divisional de solicitud n° 202002865) | |
| BR112022009216A2 (pt) | Métodos e composições para tratar um distúrbio associado a angiotensinogênio (agt) | |
| SA522440054B1 (ar) | (klkb1) تركيبات وطرق للتعديل الجيني لكاليكرين | |
| AR120341A1 (es) | COMPOSICIONES DE AGENTES DE ARNi CONTRA LA HUNTINGTINA (HTT) Y SUS MÉTODOS DE USO | |
| AR132692A1 (es) | Composiciones y métodos para inhibir la expresión del factor de coagulación xi (fxi) | |
| MX2022001004A (es) | Inhibidores de enzimas. | |
| BR112022016448A2 (pt) | Método para tratamento de doença do enxerto contra hospedeiro crônica | |
| CL2013003307A1 (es) | Agente que comprende ciazofamida o fenamidona; y su uso para tratar micosis en peces e invertebrados en todos sus estadios de desarrollo causada por hongos de los generos saprolegnia, achlya y aphanomyces (div.sol.n°1056-08). | |
| MX2021013418A (es) | Moleculas inhibidoras de acido nucleico bicatenario con cadenas de sentido acortadas. | |
| MX2024006348A (es) | Composiciones y metodos para inhibir la expresion de la proteina del virus de la hepatitis b (vhb). | |
| CO2026004645A2 (es) | Composiciones y métodos para inhibir la expresión de la proteína tau asociada a microtúbulos (mapt) | |
| MX2024012237A (es) | Composiciones y metodos para el tratamiento de enfermedades hepaticas con moleculas de acido ribonucleico interferente peque?o (siarn) dirigidas a la proteina efectora b similar a dff45 que induce la muerte celular (cideb) | |
| DOP2025000330A (es) | Composiciones y métodos para inhibir la expresión de la 3-hidroxi-3-metilglutaril-coa reductasa (hmgcr) | |
| MX2025015672A (es) | Composiciones y metodos para inhibir la expresion del factor del complemento b (cfb) | |
| MX2025014028A (es) | Arnbc de doble cadena dirigido a lpa y su uso | |
| BR112023016668A2 (pt) | Terapia de gene de combinação para tratamento de câncer metastático | |
| CL2022002859A1 (es) | Métodos de reducción o prevención de la colonización de clostridioides difficile | |
| MX2024011595A (es) | Constructos de arni para inhibir la expresion de pnpla3 y metodos de uso de los mismos | |
| PH12019500738A1 (en) | Methods of preserving the biological activity of ribonucleic acids | |
| AR126265A1 (es) | Composiciones y métodos para silenciar la expresión de myoc | |
| CL2022000217A1 (es) | Inhibidores de enzimas | |
| AR124052A1 (es) | COMPOSICIONES DE ARNi CONTRA EL FACTOR DE COAGULACIÓN V (F5) Y MÉTODOS DE USO DE LAS MISMAS | |
| CL2024003564A1 (es) | Constructos de arni para inhibir la expresión de scap y métodos de utilización de los mismos |